anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
### ADVICOR 

ADVICOR reduces LDL-C, TC, and TG, and increases HDL-C due to the individual actions of niacin and lovastatin. The magnitude of individual lipid and lipoprotein responses may be influenced by the severity and type of underlying lipid abnormality.

### Niacin 

Niacin functions in the body after conversion to nicotinamide adenine dinucleotide (NAD) in the NAD coenzyme system. Niacin (but not nicotinamide) in gram doses reduces LDL-C, Apo B, Lp(a), TG, and TC, and increases HDL-C. The increase in HDL-C is associated with an increase in apolipoprotein A-I (Apo A-I) and a shift in the distribution of HDL subfractions. These shifts include an increase in the HDL2:HDL3 ratio, and an elevation in lipoprotein A-I (Lp A-I, an HDL-C particle containing only Apo A-I). In addition, preliminary reports suggest that niacin causes favorable LDL particle size transformations, although the clinical relevance of this effect is not yet clear.

### Lovastatin 

Lovastatin has been shown to reduce both normal and elevated LDL-C concentrations. Apo B also falls substantially during treatment with lovastatin. Since each LDL-C particle contains one molecule of Apo B, and since little Apo B is found in other lipoproteins, this strongly suggests that lovastatin does not merely cause cholesterol to be lost from LDL-C, but also reduces the concentration of circulating LDL particles. In addition, lovastatin can produce increases of variable magnitude in HDL-C, and modestly reduces VLDL-C and plasma TG. The effects of lovastatin on Lp(a), fibrinogen, and certain other independent biochemical risk markers for coronary heart disease are not well characterized.
The intervention will consist of group, lasting 90 minutes in one session per week for 8 weeks. The exercises will be 5 minutes long alternating between 4 or 5 each session.
Sleep disturbances in people living with HIV (PLHIV) are frequent but their management remains insufficient. In the absence of specific recommendations, a DELPHI consensus research project was conducted in France to establish best practice. A multidisciplinary Steering Committee (STC) undertook a literature review and used it with clinical expertise to create statements that were voted on. Two profiles of healthcare professionals with significant experience in monitoring PLHIV were selected for the voting: physicians and nurses/psychologists. Votes were collected electronically, independently, and anonymously. The STC created 27 statements covering six areas: Screening of sleep disturbances, Investigation, First-line management, Referral to a specialist, Antiretroviral treatment (ARV), and Prevention. Two rounds of votes included 42 physicians and 32 nurses/psychologists. Consensus was reached for 24 out of 27 statements (89%) including: to assess quantity and quality of sleep among PLHIV at least annually, ideally using a common methodology within the medical department; to consider the temporary addition of a hypnotic treatment in cases of acute insomnia not improved by the rules of sleep hygiene, with full awareness of potential drug-drug interactions and risk of dependence; to correct ferritinaemia if <100 ng/mL before referral to a specialist when restless legs syndrome is suspected; to consider changing the time of ARV administration or an ARV switch within the same class when sleep disturbances are caused by an ARV. This DELPHI Consensus provides best practice for screening and managing sleep disturbances in PLHIV and optimising their quality of life.
Following a protocol amendment, "cohort expansion" arm was added in phase 1b with new participants enrolled to confirm the safety of the olaratumab 20 mg/kg dose prior to opening the Phase 2. Participants received intravenous infusions of olaratumab 20 mg/kg, nab-paclitaxel 125 mg/m\^2 and gemcitabine 1000 mg/m\^2 on days 1, 8, 15 of a 28-day cycle until disease progression or a criterion for discontinuation were met.
Provided is a crystal form E of bulleyaconitine A and a preparation method for the crystal form E of bulleyaconitine A. An X-ray powder diffraction spectrum of the crystal form measured by Cu-K α-ray is as shown in FIG. 1. The crystal form E of bulleyaconitine A is prepared by adding a mixed solution of alcohol and water to bulleyaconitine A, stirring to obtain a suspended solid, and centrifugally collecting the solid. The alcohol is methanol, ethanol or n-butanol. The preparation process is simple, and the obtained crystal form has high purity and is characterized by XRD, DSC, TGA, and 1HNMR to be determined as the crystal form E. The obtained bulleyaconitine A crystal is an anhydrous crystal form, and stability test results show that the crystal has good light, humidity and heat stability.
1,141,266. Novel N-substituted phthalimides. A. H. ROBINS CO. Inc. 30 Aug., 1966 [6 Dot., 1965], No. 38636/66. Heading C2C. Novel N-substituted phthalimides of the general formula wherein R is hydrogen, or a C 1-4  alkyl, aryl aralkyl or alicyclic group; R<SP>1</SP> is hydrogen or a C 1-4  alkyl group; R<SP>11</SP> is hydrogen, a halogen having an atomic weight less than 80, or a trifluoromethyl, C 1-4  alkyl or C 1-4  alkoxy group; m is 1 or 2 and n is from 1 to 4; and pharmaceutically acceptable acid addition and quaternary ammonium salts thereof are prepared by reaction of a 3-halopyrrolidine or 3-pyrrolidinyl arylsulphonate and an alkali metal salt of a phthalimide of the corresponding formulae wherein M is an alkali metal and Y is a halogen atom or an arylsulphonate group, followed optionally by conversion of the product to a pharmaceutically acceptable acid addition or quaternary ammonium salt thereof. Pharmaceutical compositions having antiarrhythmic activity comprise as active ingredient at least one N-substituted phthalimide of the first general formula above or pharmaceutically acceptable acid addition or quaternary ammonium salt thereof in association with a pharmaceutical carrier or excipient.
Pharmaceutical compsn. for oral admin. comprises a soln. of dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxyl- ate (I) (nifedipine) either (a) in polyethylene glycol carried on a porous substance in such a way that the increase in resting angle of the resulting compsn. is not >=5 degrees as compared with that of the carrier; or (b) in 0.5-30 times PVP (based on wt.). Compsns. are easily absorbable and stable forms of (I) for rapid treatment of angina pectoris. They can be formulated as a small tablets.
PURPOSE:To provide a cosmetic containing mucopolysaccharide and lecithin, and having suppressed stickiness caused by mucopolysaccharide and further improved moisturizing effect of mucopolysaccharide. CONSTITUTION:The objective cosmetic contains 0.001-5wt% (preferably 0.1-1%) mucopolysaccharide (e.g. hyaluronic acid, chondroitin-4-sulfate, etc.) and lecithin. The weight ratio of lecithin to mucopolysaccharide is >=1/10. The stickiness characteristic to mucopolysaccharide can be eliminated and the moisturizing effect can be further improved by the combined use of lecithin. The stickiness can be further suppressed by adding a lower alcohol in an am ount of from 2% to 30-40%. The cosmetic can be used in the form of solubilized system, emulsified system, powder dispersion system, etc., however, the merits of the present invention can be fully demonstrated when applied to a transparent or semitransparent face lotion.
The invention discloses a bacillus subtilis strain for high yield of nattokinase and application thereof, belonging to the technical field of microorganisms. The bacillus subtilis is preserved in the common microorganism center of China general microbiological culture Collection center (CGMCC) at 8 months and 3 days in 2020, and the preservation address is microbial research institute of China academy of sciences No. 3, North Cheng West Lu No.1 institute of Chaoyang, Beijing, and the preservation number is CGMCC No. 20479. The strain has the characteristics of good genetic stability, simple nutritional conditions, easy culture and the like. When the nattokinase is used for fermentation production of nattokinase, the level of the nattokinase produced is obviously improved, and the enzyme activity of the obtained nattokinase is 13000 IU/mL. When the method is applied to soybean and millet mixed fermentation soybean milk, the volatile basic nitrogen is obviously reduced while the activity of nattokinase is kept, and the smell is better.
PURPOSE: A composition containing a Rhododendron album extract or a fraction thereof for antioxidation is provided to remove concentration-dependent DPPH free radical and ABTS free radical and to ensure excellent antioxidation effect. CONSTITUTION: A pharmaceutical composition for antioxidation contains a Rhododendron album extract or a fraction thereof as an active ingredient. The extract is prepared using water, alcohol of C1-C2, or a mixture thereof. The fraction is a normal-hexane fraction, a chloroform fraction, an ethyl acetate fraction, a normal-butanol fraction, or a water fraction. A composition for health foods for antioxidation contains the extract or the fraction as an active ingredient. [Reference numerals] (AA) DPPH radical scavenging ability(%); (BB) Rhododendron album; (CC) Alpha-tocopherol
BACKGROUND: Growing studies revealed the association between polymorphisms in Tumor Protein TP73 (TP73) and susceptibility to cancer, especially with gynecological cancers. but, the results remained inconsistent. This meta-analysis was carried out to examine the relationship of the TP73 G4C14-to-A4T14 polymorphism (hereafter, G4C14-to-A4T14) with susceptibility to cervical cancer globally and by ethnicity.
METHODS: Eligible studies were collected by retrieving PubMed, Scopus, Web of Science, Embase, Wan Fang, and CNKI published before 25 October, 2023. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of such association.
RESULTS: A total of 10 case-control studies with 1804 cervical cancer cases and 2433 healthy controls were included to this study. The pooled results showed that TP73 G4C14-to-A4T14 polymorphism was not associated with cervical cancer risk in overall. in terms of stratified analyses by ethnicity, this polymorphism was not associated with risk of cervical cancer among East-Asian women. however,  there was a significant association based source of control among hospital-based studies.
CONCLUSIONS: Inconsistent with previous meta-analyses, our pooled results revealed that TP73 G4C14-to-A4T14 polymorphism might not be a risk factor for development of cervical cancer globally and among East-Asian women. Moreover, further studies examining the effect of gene-gene and gene-environment interactions may eventually provide a better knowledge.
A Japanese woman in her 70s was referred to our hospital for the evaluation and treatment of high intraocular pressure (IOP) in her right eye. She had undergone bilateral cataract surgeries and the insertion of hydrophilic acrylic intraocular lenses (IOLs). We performed trabeculotomy and trabeculectomy to lower her right IOP; thereafter, a circular opacity was observed on the right eye's IOL surface. We removed the right IOL because that eye's vision had decreased due to IOL opacification. The analysis of the removed IOL revealed that the main opacity component was calcium phosphate. This is the first post-glaucoma-surgery IOL calcification case report.
The invention discloses a domestic cleaning enzyme. The invention contains a large amount of plant active enzyme, and is canned by high-temperature sterilization, thus being the pure plant cleaning stock solution. No chemical additive, no residue and environment purification. The fermentation stock solution can be used for cleaning kitchens, washing tableware and fruit cooked fish meat to remove pesticide residues, and can also be used for cleaning skin, clothes and environment; the stock solution prepared by the formula through a special process is used for cleaning and can clean a kitchen: no toxicity, no smell and no residue. When the fruit, vegetable and fish meat are washed, pesticide residues can be removed, so that the health of eaters is guaranteed, and simultaneously, silt can be separated, so that the cleaning capability of the product is improved; the traditional Chinese medicine in the raw liquid is cleaned, so that the skin is maintained, and the skin immunity is enhanced. The cleaning stock solution can decompose dirt into small molecular organic residues, so that the dirt is more easily decomposed by bacteria, converted into natural elements, purified in ecology and fed back to the nature, and the environmental protection of the product is improved.
A sea cucumber compound product comprises sea cucumber nano powder and Panax Notoginseng saponins extractive.The preparation method of sea cucumber compound product comprises: (A) treating the raw material; and cutting alive sea cucumber, eviscerating, cleaning and placing it in a sealed container; (B) heating at 70-130 ? and gelatinizing for 1 min-20 h; (C) freeze-drying until the water content is smaller than 10 wt%; (D) coarse crushing to obtain cucumber powder of 100-300 mesh; (E) super-micro crushing by a jet mill to a fineness of 100-3000 mesh; (F) nano-crushing by a high-energy ball mill pulverizer to a fineness of 10-1000nm; and (G) mixing the sea cucumber nano powder and Panax Notoginseng saponins extractive at 99-80%:1-20% weight ratio. The content of sea cucumber polysaccharide is 2.5-8.1 wt%. The content of Panax Notoginseng saponins is 0.3-14.0 wt %. The sea cucumber compound product has complementary and synergistic effect, enhances the pharmacological action and eliminates the side effect of single agent. It can be used for health protection and medicament.
Sleep disorders are common in children and affect neurological development with important cognitive, emotional and behavioral repercussions. There is a high prevalence of sleep disorders (SD) in neurodevelopmental disorders (NDD) such as autism spectrum disorder (ASD) and attention-deficit hyperactivity disorder (ADHD). Sleep disorders in pediatric population have a prevalence of 6-25%, while in children with NDD this number rises to 50-80%. In NDDs, higher rates of difficulties in falling asleep, nocturnal awakenings and daytime sleepiness are observed. Disturbances in the circadian rhythm as well as respiratory sleep disorders are also observed. Consequently, there is a decrease in alertness for daytime activities with increased behavioral disorders, emotional problems and academic difficulties associated with executive and memory dysfunctions. Sleep assessment has to be a systemic part in the clinical evaluation of children with NDDs, so as to give a convenient diagnosis and treatment in each case, allowing to improve the quality of life of children and their families.
Drought is one of the main factors contributing to tree mortality worldwide and drought events are set to become more frequent and intense in the face of a changing climate. Quantifying water stress of forests is crucial in predicting and understanding their vulnerability to drought-induced mortality. Here, we explore the use of high-resolution spectroscopy in predicting water stress indicators of two native Australian tree species, Callitris rhomboidea and Eucalyptus viminalis. Specific spectral features and indices derived from leaf-level spectroscopy were assessed as potential proxies to predict leaf water potential (Ψleaf), equivalent water thickness (EWT) and fuel moisture content (FMC) in a dedicated laboratory experiment. New spectral indices were identified that enabled very high confidence linear prediction of Ψleaf for both species (R2 > 0.85) with predictive capacity increasing when accounting for a breakpoint in the relationships using segmented regression (E. viminalis, R2 > 0.89; C. rhomboidea, R2 > 0.87). EWT and FMC were also linearly predicted to a high accuracy (E. viminalis, R2 > 0.90; C. rhomboidea, R2 > 0.80). This study highlights the potential of spectroscopy as a tool for predicting measures of plant water noninvasively, enabling broader applications for monitoring and managing plant water stress.
PURPOSE: To investigate the variability in urinary stone composition analysis due to sampling and suggest potential solutions.
MATERIALS AND METHODS: We collected 1,135 stone fragments from 149 instances that had undergone a stone removal at Hanoi Medical University Hospital from January 2022 to August 2022. Each fragment was ground into fine powder and divided into separate specimens if the amount was abundant. For composition analyzing every specimen, Fourier transform infrared spectroscopy was performed. The composition of a given fragment was the average of its belonging specimens. The variability in composition was assessed on the fragment level (i.e., between fragments of an instance). We defined an instance as "significantly variable" if the maximum difference in any composition across its belonging fragments was equal to or greater than a given threshold.
RESULTS: On average, there were 7.6±3.3 stone fragments per instance and 2.3±0.5 specimens per fragment. We found that the variability could be substantial on the fragment level. Eighty-nine (69.5%) and 70 (54.7%) out of 128 multiple-component instances were significantly variable if the threshold was set at 20% and 30%, respectively. The variability of an instance on the fragment level was correlated with the size of fragment and the number of components.
CONCLUSIONS: Our study demonstrated the significant variability in urinary stone composition and showed that it correlated with the size and the impurity of samples. Mapping denotation while sampling and analyzing as well as reporting the composition of individual fragments could be valuable to reduce potential variability.
Methods, products and kits are provided for attaching agents to tissue with a linking molecule in the presence of transglutaminase. The linking molecule and/or agent is a substrate of transglutaminase. The agent can be a nonprotein or an enzyme such as cholinesterase or phosphodiesterase. The transglutaminase may be exogenously added or be endogenous in tissue. In specific embodiments, the linking molecule contains at least two contiguous linked glutamines or at least three contiguous linked lysines. A conjugate of the agent and the linking molecule may be applied to tissue, and in the presence of transglutaminase covalently bonded to the tissue via the linking molecule. A complementary linking molecule rich in lysines may be first attached to the tissue in the presence of transglutaminase, and then covalently bonded to a glutamine-containing linking molecule of the conjugate in the presence of transglutaminase. In another embodiment, a linking molecule containing multiple glutamines is covalently bonded to tissue in the presence of transglutaminase, and an agent containing multiple lysines is covalently bonded to the linking molecule in the presence of transglutaminase. Alternatively, the linking molecule contains multiple lysines and the agent contains multiple glutamines. Two tissues can be sealed together by holding the tissues in contact with each other in the presence of transglutaminase.
Twelve subjects between the ages of 18 years and 55 years who have had Type 1 Diabetes Mellitus for more than five years and have had tight control of their diabetes as determined by screening blood work will be invited to participate. Each study subject will undergo two hypoglycemic clamp studies (a procedure where the blood sugar is closely regulated with intravenous insulin and glucose.) In these hypoglycemic clamp studies, cognitive testing will be performed during 90 minutes of normal blood glucose followed by 90 minutes of hypoglycemia. During the hypoglycemic period, either the MCFA or a placebo will be administered. Each subject will experience both conditions. The order in which the MCFA is given will be randomized.
Optimal lipid-lowering therapy (LLT) is a mainstay for the therapeutic management of atherosclerotic vascular disease. Cardiac and cerebrovascular adverse events and progression of atherosclerosis are, indeed, reduced in proportion to the achieved LDL cholesterol (LDL-C) levels.In addition, regression of atherosclerotic plaques with optimal LLT has been observed. However, optimal LLT with statin and ezetimibe, might be limited by the onset of adverse effects (i.e. disabling myalgias, diarrhea) with are usually dose -dependent, and the maximum tolerated statin dose might be insufficient to reach the recommended LDL-C goals. The advent of proprotein convertase subtilisin kexin type 9 inhibitors (PCSK9i) has allowed the achievement of very low LDL-C levels, and the fulfillment of the recommended LDL-C targets. However, while the experience with PCSK9i in patients with coronary artery disease has been wide, and coronary plaque regression has been documented, little is known regarding carotid plaque regression following therapy with PCSK9i. Only a few case reports have been published, and no observational study has been carried out so far. Furthermore, morphological carotid plaque stabilization has a prognostic role, and the possibility of its early achievement with PCSK9i may be relevant, especially in the context of percutaneous or surgical carotid interventions.
Methods and systems for an integrated sensor network are described. In one embodiment, sensor data may be accessed from a plurality of motion sensors and a bed sensor deployed in a living unit for a first time period. An activity pattern for the first time period may be identified based on at least a portion of sensor data associated with the first time period. The activity pattern may represent a physical and cognitive health condition of a person residing in the living unit. Additional sensor data may be accessed from the motion sensors and the bed sensor deployed for a second time period. A determination of whether a deviation of the activity pattern of the first time period has occurred for the second time period may be performed. An alert may be generated based on a determination that the derivation has occurred. In some embodiments, user feedback is captured on the significance of the alerts, and the alert method is customized based on this feedback. Additional methods and systems are disclosed.
Presently, patients having intermediate-risk prostate carcinoma have to make a very difficult decision regarding treatment, as active surveillance will not immediately alter the current quality of life. However, because there is a risk of progressive disease or due to patient anxiety due to an untreated tumor, many patients opt for active treatment, often using radiation or prostatectomy, and sometimes in combination with androgen deprivation. Unfortunately, radiation, surgery, and androgen deprivation have multiple and potentially profound side effects including sexual, urinary, and bowel complications. As a small fraction of men dies from this disease, the number of men needed to treat to prevent one death is large, resulting in many men with side effects or complications to help prevent the one death. It is for these reasons that there is a major need for focal therapy for this group of patients who most commonly are treated actively with surgery or radiation; such focal therapy could ablate the detected tumor(s) within the prostate, control the disease while avoiding side effects of whole gland therapies and controlling tumor growth within the prostate detected by (multiparameter-) MRI and histopathologically confirmed by biopsy. MagForce NanoTherm® Therapy offers this option by noninvasive ablation of small tumors in a 1-2 ml target volume of the prostate, a treatment that is not possible with any other technology on the market.

This study evaluates the use of NanoTherm ablation as a method of treating these intermediate grade lesions allowing patients to return to active surveillance without definitive treatment such as external beam radiation or prostatectomy.